Antistax® in Patients With Chronic Venous Insufficiency

Inclusion Criteria: * Male or female * Between 25 and 75 years of age * CVI I or CVI II (without expanded trophic disturbances) * Willing and able to give written informed consent prior to participation in the study Exclusion Criteria: Concomitant disease(s) exclusion criteria: * Decompensated cardiac insufficiency * Edema not due to venous disease of the legs (e.g. latent cardiac insufficiency, renal insufficiency, lymph edema, etc) * Peripheral arterial disease (ankle/arm pressure index \< 0.9) * Current acute phlebitis or thrombosis * Renal insufficiency (Serum creatinine \> 1.5 mg/dl) * Liver disease (SGPT (ALAT) \> 3x upper limit of normal) * Other diseases: insulin-dependent diabetes mellitus, neuropathies, hyper- or hypocalcaemia, malignancies * Anamnestic indications of diabetic microangiopathy or polyneuropathy * Drug and/or alcohol abuse * Severe climacteric complaints * Immobility * Avalvulia * Klippel-Trénaunay-Weber-Syndrome (Naevus varicosis osteohypertrophicus, Haemangiectasia hypertrophicans) * State after pulmonary embolism * Recognized hypersensitivity to the trial drug ingredients * Current florid venous ulcus * Clinical indication for a necessary, specific phlebologic acute treatment, e.g. compressive treatment, phlebectomy, etc. Previous treatment(s) exclusion criteria: * Treatment with venous drugs within the last 4 weeks * Treatment with laxatives which affect fluid or electrolyte balance within the last 8 days * Changes in or unstable response to…